Sun Yat-sen University: clinical-trial pipeline
Sun Yat-sen University is the sponsor of 1,674 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 552 are not yet finished and 16 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 645 |
| Phase 2 | 571 |
| Phase 3 | 258 |
| Phase 4 | 71 |
| Phase 1/2 | 51 |
| Phase 1 | 34 |
| Phase 2/3 | 31 |
| Early phase 1 | 13 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 686 |
| Completed | 365 |
| Recruiting | 306 |
| Not yet recruiting | 167 |
| Active, not recruiting | 79 |
| Withdrawn or not authorised | 34 |
| Terminated | 31 |
| Suspended or halted | 6 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 1,147 |
| Gastroenterology and liver | 273 |
| Ophthalmology | 180 |
| Metabolic and endocrine (diabetes, obesity) | 77 |
| Nephrology and urology | 73 |
| Cardiovascular | 61 |
| Immunology and rheumatology | 40 |
| Infectious disease and vaccines | 40 |
| Women's health and obstetrics | 40 |
| Rare and genetic diseases | 25 |
| Psychiatry and mental health | 17 |
| Musculoskeletal | 15 |
Countries
| Country | Trials |
|---|---|
| China | 1,520 |
| India | 1 |
| Singapore | 1 |
| Taiwan | 1 |
| United States | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | IC ECG Combined With Ultrasound Bubble Test for PICC Tip Positioning Among Oncology Adult… |
| 2026-10-20 | New trial posted | Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable… |
| 2026-10-20 | New trial posted | Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Cl… |
| 2026-10-19 | New trial posted | Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU Patients |
| 2026-10-16 | New trial posted | Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan… |
| 2026-10-14 | New trial posted | Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunothe… |
| 2026-10-14 | New trial posted | HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World S… |
| 2026-10-13 | New trial posted | Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition A… |
| 2026-10-07 | New trial posted | A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First… |
| 2026-09-29 | New trial posted | Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1… |
| 2026-09-18 | New trial posted | Multi-Theory Model-Based AI Agent Intervention for Smoking Cessation in Early-Stage Cance… |
| 2026-09-17 | New trial posted | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases F… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Phase 2 | Recruiting | China |
| NCT07753642 | Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma | Phase 2 | Not yet recruiting | China |
| NCT07277842 | PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer | Phase 3 | Not yet recruiting | China |
| NCT07088263 | Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer | Phase 3 | Recruiting | China |
| NCT07028047 | Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study | Phase 1 | Not yet recruiting | |
| NCT05080010 | Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma | Phase 3 | Recruiting | China |
| NCT05491811 | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation | Phase 2 | Active, not recruiting | China |
| NCT06551220 | Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns | Not applicable | Recruiting | China, United States |
| NCT07674524 | Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC | Not applicable | Not yet recruiting | China |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma | Phase 2 | Not yet recruiting | |
| NCT07615283 | Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma | Phase 1/2 | Not yet recruiting | China |
| NCT06609850 | The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Car… | Not applicable | Recruiting | China |
| NCT01653223 | Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery | Not applicable | Recruiting | China |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | Phase 1/2 | Not yet recruiting | |
| NCT06695936 | Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcino… | Not applicable | Not yet recruiting | |
| NCT06377735 | BAI-BACE for Advanced Lung Squamous Cell Carcinoma | Not applicable | Recruiting | China |
| NCT06043999 | Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients | Not applicable | Recruiting | China |
| NCT05794971 | Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases | Phase 3 | Recruiting | China |
| NCT07501351 | Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Fail… | Phase 2 | Recruiting | China |
| NCT07622771 | Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer:… | Phase 2 | Recruiting | China |
| NCT05727163 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or With… | Phase 2 | Recruiting | China |
| NCT06912074 | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esop… | Phase 2 | Recruiting | China |
| NCT05979961 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | Phase 3 | Active, not recruiting | China |
| NCT07603063 | A Descriptive Study of the Correlation Between Postpartum Depression and Body Image Dissatisfaction, Self-obj… | Not applicable | Not yet recruiting | |
| NCT03493048 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | Phase 2 | Active, not recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Sun Yat-sen University clinical trials: 552 open, 289 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/sun-yat-sen-university/, data as of 2026-10-25.